The promise of thalidomide: Evolving indications

Drugs of Today

Volumn 40, Issue 3, 2004, Pages 197-204

  Joglekar, Swati ^a   Levin, Mark ^b,c  

^a LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Holy Name Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GAMMA INTERFERON; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; PREDNISONE; SELCID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINCRISTINE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APHTHOUS ULCER; CACHEXIA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; ERYTHEMA NODOSUM LEPROSUM; GENITAL ULCER; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; KAPOSI SARCOMA; KIDNEY CARCINOMA; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; REVIEW;

CACHEXIA; CARCINOMA, RENAL CELL; CLINICAL TRIALS; ERYTHEMA NODOSUM; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; LEPROSY, LEPROMATOUS; MULTIPLE MYELOMA; SARCOMA, KAPOSI; THALIDOMIDE; ULCER;

EID: 2342647946     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.3.820083     Document Type: Review

References (53)

1. Diggle, G.E. Thalidomide: 40 years on. Int J Clin Pract 2001, 55: 627-31.
2. Nightingale, S.L. From the Food and Drug Administration. JAMA 1998, 280: 872.
3. Peuckmann, V., Fisch, M., Bruera, E. Potential novel uses of thalidomide: Focus on palliative care. Drugs 2000, 60: 273-92.
4. Celgene. Thalomid® (thalidomide) capsules prescribing information. Warren, NJ 1998.
5. Calabrese, L., Resztak, K. Thalidomide revisited: Pharmacology and clinical applications. Exp Opin Invest Drugs 1998, 7: 2043-60.
6. Trapnell, C.B., Donahue, S.R., Collins, J.M. et al. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther 1999, 65: 483-90.
7. Zwingenberger, K., Wnendt, S. Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations. J Inflamm 1995-96, 46: 177-211.
8. Aukrust, P., Liabakk, N.B., Muller, F. et al. Thalidomide. Med Lett Drugs Ther 1998, 40: 103-4.
9. Balog, D.L., Epstein, M.E., Amodio-Groton, M.I. HIV wasting syndrome: Treatment update. Ann Pharmacother 1998, 32: 446-58.
10. Calabrese, L., Resztak, K. Thalidomide revisited: Pharmacology and clinical application subclasses, tumor factor and IFN-gamma levels in patients with type II lepra reactions. Exp Opin Invest Drugs 1998, 7: 2043-60.
11. Nogueira, A.C., Neubert, R., Helge, H. et al. Thalidomide and the immune system. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994, 55: 77-92.
12. D'Amato, R.J., Loughnan, M.S., Flynn, E. et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994, 91: 4082-5.
13. Kenyon, B.M., Browne, F., D'Amato, R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997, 64: 971-8.
14. Keifer, J.A., Guttridge, D.C., Ashburner, B.P., Baldwin, A.S. Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001, 276: 22382-7.
15. Davies, F.E., Raje, N., Hideshima, T. et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98: 210-6.
16. Partida-Sánchez, S., Favila-Castillo, L., Pedraza-Sánchez, S. et al. IgG antibody subclasses, tumor factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment. Int Arch Allergy Immunol 1998, 116: 60-6.
17. Sheskin, J., Convit, J. Results of a double-blind study of the influence of thalidomide on lepra reaction. Int J Lepr 1969, 37: 135-46.
18. Waters, M.F.R. An internally controlled double-blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev 1971, 42: 26-42.
19. Jemal, A., Thomas, A., Murray, T., Thun, M. Cancer statistics, 2002. CA Cancer J Clin 2002, 52: 23-47.
20. Rajkumar, S.V. Thalidomide in multiple myeloma. Oncology 2000, 14 (12 Suppl. 13): 11-6.
21. Anderson, K. Advances in disease biology: Therapeutic implications. Semin Hematol 2001, 38 (2 Suppl. 3): 6-10.
22. Singhal, S., Mehta, J., Barlogie, B. et al. Antitumor activity of thalidomide in refractory multipie myeloma. N Engl J Med 1999, 341: 1565-71.
23. Rajkumar, S.V., Fonseca, R., Dispenzieri, A. et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000, 75: 897-902.
24. Weber, D.M., Rankin, K., Gavino, M. et al. Thalidomide with dexamethasone for resistant multiple myeloma. Blood 2000, 96: 167a.
25. Dimopoulos, M.A., Zervas, K., Galani, E. et al. Thalidomide and dexamethasone combination for multiple myeloma refractory to dexamethasone-based regimens. Blood 2000, 96 (Suppl. 1): 286b.
26. Palumbo, A., Giaccone, L., Bertola, A. et al. Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma. Blood 2000, 96 (Suppl. 1): 292b.
27. Coleman, M., Leonard, J.P., Nahum, K., Michaeli, J. Nonmyelosuppressive therapy with BLT-D ([Biaxin], low-dose thalidomide, and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma. Blood 2000, 96: 167a.
28. Durie, B.G., Stepan, D.E. Low dose thalidomide alone and in combination: long-term follow-up. In: Program with abstracts-on-disk of the 43rd annual meeting of the American Society of Hematology. American Society of Hematology, Washington, DC 2001.
29. Richardson, P.G., Schlossman, R.L., Hideshima, T. et al. A phase I study of oral CC5013, an immunomodulatory thalidomide (thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). In: Program with abstracts-on-disk of the 43rd annual meeting of the American Society of Hematology. American Society of Hematology, Washington, DC 2001.
30. Rovelli, A., Arrigo, C., Nesi, F. et al. The role of thalidomide in the treatment of refractory graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 1998, 21: 577-81.
31. Browne, P.V., Weisdorf, D.J., Defor, T. et al. Responses to thalidomide therapy in chronic graft-versus-host disease. Bone Marrow Transplant 2000, 26: 865-9.
32. Haslett, P.A. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1998, 25 (Suppl. 6): 53-7.
33. Bach, M.C., Valenti, A.J., Howell, D.A., Smith, T.J. Odynophagia from aphthous ulcers of the pharynx and esophagus in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988, 109: 388-9.
34. Jacobson, J.M., Greenspan, J.S., Spritzler, J. et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS clinical trials group. N Engl J Med 1997, 336: 1487-93.
35. Alexander, L.N., Wilcox, C.M. A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res Hum Retrovir 1997, 13: 301-4.
36. De Wazieres, B., Gil, H., Magy, N. et al. Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients. Rev Med Interne 1999, 20: 567-70.
37. Ball, S.C., Sepkowitz, K.A., Jacobs, J.L. Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: Case report and review. Am J Gastroenterol 1997, 92: 169-70.
38. Little, R.F., Wyvill, K.M., Pluda, J.M. et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000, 18: 2593-602.
39. Olencki, T., Malhi, S., Mekhail, T. et al. Phase I trial of thalidomide and interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2003, 22: 402, Abstr. 1554.
40. Amato, R.J., Schell, J., Thompson, N., Moore, R., Miles, B. Phase II study of thalidomide + interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 2003, 22: 387, Abstr. 1556.
41. Sastry, P.S. Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis. Med Hypotheses 1999, 53: 76-7.
42. Haslett, P.A., Klausner, J.D., Makonkawkeyoon S. et al. Thalidomide stimulates T cell responses and IL-12 production in HIV-infected patients. AIDS Res Hum Retrovir 1999, 15: 1169-79.
43. Daly, B.B., Shuster, S. Antipruritic action of thalidomide. Acta Derm Venereol 2000, 80: 24-5.
44. McCormick, P.A., Scott, F., Epstein, O. et al. Thalidomide as therapy for primary biliary cirrhosis: A double-blind placebo controlled pilot. J Hepatol 1994, 21: 496-9.
45. Silva, S.R., Viana, P.C., Lugon, N.V. et al. Thalidomide for the treatment of uremic pruritus: A crossover randomized double-blind trial. Nephron 1994, 67: 270-3.
46. Celgene Pharmaceuticals Inc. Thalidomide package insert. Warren, NJ 1999.
47. Govindarajan, R., Maddox, A., Safan, M. et al. The efficacy of thalidomide and irinotecan in metastatic colorectal carcinoma (phase II study). Proc Annu Meet Am Soc Clin Oncol 2002, 21: 2222, Abstr.
48. Dal Lago, L., Di Leone, L., Fernandes, S. et al. Clinical and pharmacokinetic study of thalidomide in patients with advanced refractory metastatic colorectal cancer. Proc Annu Meet Am Soc Clin Oncol 2002, 1870, Abstr.
49. Long, G., Vredenburgh, J., Rizziere, D.A. et al. Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 1998, 17: 181, Abstr.
50. Fine, H.A., Loeffler, J.S., Kyritsis, A. et al. A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas. Proc Annu Meet Am Soc Clin Oncol 1997, 16: 1372, Abstr.
51. Figg, W.D., Bergan, R., Brawley, et al. Randomized phase II study of thalidomide in androgen-independent prostate cancer. Proc Annu Meet Am Soc Clin Oncol 1997, 16: 333, Abstr.
52. Dixon, S.C., Bauer, K.S., Zalles, A. et al. Thalidomide effects on angiogenesis and PSA expression. Proc Annu Meet Am Assoc Cancer Res 1997, 38: 2866.
53. Eisen, T., Boshoff, C., Vaughan, M.M. et al. Antiangiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancers with thalidomide: A phase II study. Proc Annu Meet Am Soc Clin Oncol 1998, 17: 441, Abstr.